HomeInsightsEPS

Concord Drugs Ltd EPS

Concord Drugs Ltd EPS

stocks purchased

₹ 0.0 Cr

Volume transacted

stocks purchased

8.4 K

stocks traded

Last Updated time: 18 Sep 9.00 AM

Image

Concord Drugs Ltd

NSE: CONCORDDRUGS

EPS

0.01

Last updated: 18 Sep 24

Key Highlights

  • The Earning per Share of Concord Drugs Ltd is ₹ 0.01 as of 18 Sep 24.
  • The Earning per Share of Concord Drugs Ltd changed from ₹ 0.21 to ₹ 0.03 over 9 quarters. This represents a CAGR of -57.89% .

Historical Earning per Share of Concord Drugs Ltd

No data available

* All values are in

Company Fundamentals for Concord Drugs Ltd

Market Cap

36 Cr

EPS

0.0

P/E Ratio (TTM) *

0.0

P/B Ratio (TTM) *

1.1

Day’s High *

38.5

Day’s Low

36.39

DTE *

0.5

ROE *

1.4

52 Week High

61.5

52 Week Low

30.06

ROCE *

5.0

Share price Over Time

1M

1Y

3Y

5Y

Monitoring Concord Drugs Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Share Price

Date
leftPriceleft
18 Sep 202436.87
17 Sep 202437.89
16 Sep 202437.4
13 Sep 202437.69
12 Sep 202437.73
11 Sep 202437.66
10 Sep 202438.26
09 Sep 202438.2
06 Sep 202437.56
05 Sep 202437.74

BlinkX Score for Concord Drugs Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Concord Drugs Ltd

Market Value

37

-0.2 X

Value addition

Asset Value

45

* All values are in Rupees

Competitive Comparison of EPS

Historical Market Cap of Concord Drugs Ltd

No data available

* All values are in crore

Historical Revenue of Concord Drugs Ltd

No data available

* All values are in crore

Historical EBITDA of Concord Drugs Ltd

No data available

* All values are in crore

Historical Net Profit of Concord Drugs Ltd

No data available

* All values are in crore

Dividend per Share (DPS) Over Time

No data available

Concord Drugs Ltd News Hub

News

Concord Drugs fixes board meeting date

Concord Drugs will hold a meeting of the Board of Directors of the Company on 6 September ...

Read more

03 Sep 202411:10

News

Concord Drugs to table results

Concord Drugs will hold a meeting of the Board of Directors of the Company on 9 August 202...

Read more

06 Aug 202416:20

News

Concord Drugs postpones board meeting

Concord Drugs has postponed the meeting of the Board of Directors which was scheduled to b...

Read more

25 May 202411:26

News

Concord Drugs declare Quarterly Result

Concord Drugs will hold a meeting of the Board of Directors of the Company on 25 May 2024 ...

Read more

16 May 202412:41

News

Concord Drugs to announce Quarterly Result

Concord Drugs will hold a meeting of the Board of Directors of the Company on 13 February ...

Read more

07 Feb 202419:05

News

Concord Drugs to conduct board meeting

Concord Drugs will hold a meeting of the Board of Directors of the Company on 14 November ...

Read more

08 Nov 202315:27

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

FAQs for EPS of Concord Drugs Ltd

What is the EPS of Concord Drugs Ltd stock?

The Earnings Per Share (EPS) of Concord Drugs Ltd is 0.01. An EPS is the amount of net income attributed to each share of a common stock.

How is Concord Drugs Ltd EPS calculated?

The EPS of Concord Drugs Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Concord Drugs Ltd report its EPS?

Concord Drugs Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Concord Drugs Ltd EPS?

Factors that influence the EPS of Concord Drugs Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Concord Drugs Ltd EPS growth indicate future performance?

Yes, consistent growth in Concord Drugs Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*